Krebs Biochemicals & Industries Ltd (KREBSBIO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 142337, "name": "Krebs Biochem", "stock_name": "Krebs Biochem", "full_name": "Krebs Biochemicals & Industries Ltd", "name_url": "stocks-analysis/krebs-biochem", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "65.97", "chg": 1.21, "chgp": "1.87%", "dir": 1, "prev_price": "64.76", "mcapval": "139.00 Cr", "mcap": "Micro Cap", "scripcode": 524518, "symbol": "KREBSBIO", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE268B01013", "curr_date": "Jun 19, 03:30 PM", "curr_time": "01:26 AM", "last_traded_at": "Jun 19, 03:30 PM IST", "bse_nse_vol": "1.59 k", "exc_status": "Active", "traded_date": "Jun 19, 2026", "traded_date_str": "2026 06 19", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/krebs-biochem-142337-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Krebs Biochemicals & Industries Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/krebs-biochemicals-industries-ltd-is-rated-strong-sell-4054136", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/KrebsBiochemica_mojoScore_4054136.png", "date": "2026-06-15 10:10:37", "description": "Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 15 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Krebs Biochemicals & Industries Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/krebs-biochemicals-industries-ltd-is-rated-strong-sell-4026175", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/KrebsBiochemica_mojoScore_4026175.png", "date": "2026-06-01 10:10:19", "description": "Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 01 June 2026, providing investors with the latest insights into its performance and prospects." }, { "title": "Krebs Biochemicals & Industries Ltd Locks at Upper Circuit With 4.78% Gain — Buyers Queue, Sellers Absent", "link": "https://www.marketsmojo.com/news/stocks-in-action/krebs-biochemicals-industries-ltd-hits-upper-circuit-amid-strong-buying-pressure-4016315", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/KrebsBiochemica_stocks_hitting_upper_circuit_4016315.png", "date": "2026-05-27 10:00:09", "description": "At Rs 68.14, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Krebs Biochemicals & Industries Ltd locked at its upper circuit of 4.78% on 27 May 2026, with buyers queuing and no sellers willing to part with shares." }, { "title": "Krebs Biochemicals & Industries Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent", "link": "https://www.marketsmojo.com/news/stocks-in-action/krebs-biochemicals-industries-ltd-hits-upper-circuit-amid-strong-buying-momentum-4013269", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/KrebsBiochemica_stocks_hitting_upper_circuit_4013269.png", "date": "2026-05-26 10:00:11", "description": "At Rs 64.9, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Krebs Biochemicals & Industries Ltd locked at its upper circuit of 5% on 26 May 2026, with buyers queuing and no sellers willing to part with shares." }, { "title": "A 5% Single-Day Surge Takes Krebs Biochemicals & Industries Ltd to Its Upper Circuit Limit of Rs 61.81", "link": "https://www.marketsmojo.com/news/stocks-in-action/krebs-biochemicals-industries-ltd-hits-upper-circuit-amid-strong-buying-pressure-4010657", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/KrebsBiochemica_stocks_hitting_upper_circuit_4010657.png", "date": "2026-05-25 11:00:09", "description": "At Rs 61.81, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Krebs Biochemicals & Industries Ltd locked at its upper circuit of 4.99% on 25 May 2026, with buyers queuing and no sellers willing to part with shares." }, { "title": "Krebs Biochemicals & Industries Ltd Declines 2.33% Amid Financial Struggles and Market Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/krebs-biochemicals-industries-ltd-declines-233-amid-financial-struggles-and-market-pressure-4009546", "imagepath": "", "date": "2026-05-24 16:00:52", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>May 20:</strong> Stock hits lower circuit amid heavy selling pressure</p>\n <p><strong>May 21:</strong> Q4 FY26 results reveal mounting losses</p>\n <p><strong>May 22:</strong> Reports flat quarterly performance amid prolonged downtrend</p>\n <p><strong>Week Close:</strong> Rs.56.50 (-2.33%) vs Sensex +0.50%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.57.85</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.56.50</div><div clas..." }, { "title": "Are Krebs Biochemicals & Industries Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-krebs-biochemicals-industries-ltd-latest-results-good-or-bad-4006954", "imagepath": "", "date": "2026-05-22 19:22:28", "description": "Krebs Biochemicals & Industries Ltd continues to face significant operational challenges, as evidenced by its latest financial results for Q4 FY26. The company reported net sales of ₹6.81 crores, which reflects an 11.64% year-on-year growth compared to ₹6.10 crores in Q4 FY25. However, this growth is overshadowed by a sequential decline of 6.33% from ₹7.27 crores in Q3 FY26, indicating revenue volatility.\n\nThe net loss for the quarter was ₹2.34 crores, which represents a 25.24% improvement from the previous quarter's loss of ₹3.13 crores, yet it remains significantly worse than the ₹8.27 crores loss reported in Q4 FY25. The company's PAT margin stood at -34.36%, an improvement from -43.05% in the prior quarter, but still highlights ongoing profitability challenges.\n\nKrebs Biochemicals has a negative book value of ₹-67.83 per share, reflecting a troubling financial position with shareholder equity at ₹-146.2..." }, { "title": "Krebs Biochemicals & Industries Ltd Reports Flat Quarterly Performance Amid Prolonged Downtrend", "link": "https://www.marketsmojo.com/news/stocks-in-action/krebs-biochemicals-industries-ltd-reports-flat-quarterly-performance-amid-prolonged-downtrend-4004116", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/KrebsBiochemica_fintrenddot_4004116.png", "date": "2026-05-22 08:00:03", "description": "Krebs Biochemicals & Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a tentative stabilisation after a period of significant decline. Despite some improvement in quarterly profitability metrics, the company continues to grapple with steep revenue contraction and persistent losses over the nine-month period, reflecting ongoing challenges in its business operations and market positioning." }, { "title": "Krebs Biochemicals Q4 FY26: Mounting Losses Signal Deepening Crisis", "link": "https://www.marketsmojo.com/news/result-analysis/krebs-biochemicals-q4-fy26-mounting-losses-signal-deepening-crisis-4003695", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/KrebsBiochemica_quaterlyResult_4003695.png", "date": "2026-05-21 20:00:32", "description": "Krebs Biochemicals & Industries Ltd., a micro-cap pharmaceutical manufacturer specialising in Active Pharmaceutical Ingredients through fermentation, reported a net loss of ₹2.34 crores in Q4 FY26 (Mar'26), marking the seventh consecutive quarter of losses. With a market capitalisation of just ₹122.00 crores, the company's shares declined 2.15% to ₹53.81 following the results, extending a brutal 27.28% decline over the past year and trading 52.76% below its 52-week high of ₹113.90." } ], "total": 156, "sid": "142337", "stock_news_url": "https://www.marketsmojo.com/news/krebs-biochemicals-industries-142337" }, "announcements": [ { "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance", "datetime": "29-May-2026", "details": "The Company has enclosed herewith Annual Secretarial Complince Report for the yaer ended 31.03.2026.", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "22-May-2026", "details": "The Company has enclosing herewith copy of newspapers advetiement of financial resulst for the quarter and yaer ended 31.03.2026.", "source": "BSE" }, { "caption": "Result For FY Ended 31.03.2026", "datetime": "21-May-2026", "details": "Audited Results for fiancial yaer ended 31.03.2026", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "", "data": [ { "txt": "Krebs Biochemicals & Industries Ltd has announced <strong>21:100</strong> rights issue, ex-date: 31 Jan 19", "dt": "2019-01-31", "middle_text": "Rights Issue" } ] } ] }

Key Events This Week

May 20: Stock hits lower circuit amid heavy selling pressure

May 21: Q4 FY26 results reveal mounting losses

May 22: Reports flat quarterly performance amid prolonged downtrend

Week Close: Rs.56.50 (-2.33%) vs Sensex +0.50%

Read full news article

Are Krebs Biochemicals & Industries Ltd latest results good or bad?

2026-05-22 19:22:28

Krebs Biochemicals & Industries Ltd continues to face significant operational challenges, as evidenced by its latest financial results for Q4 FY26. The company reported net sales of ₹6.81 crores, which reflects an 11.64% year-on-year growth compared to ₹6.10 crores in Q4 FY25. However, this growth is overshadowed by a sequential decline of 6.33% from ₹7.27 crores in Q3 FY26, indicating revenue volatility. The net loss for the quarter was ₹2.34 crores, which represents a 25.24% improvement from the previous quarter's loss of ₹3.13 crores, yet it remains significantly worse than the ₹8.27 crores loss reported in Q4 FY25. The company's PAT margin stood at -34.36%, an improvement from -43.05% in the prior quarter, but still highlights ongoing profitability challenges. Krebs Biochemicals has a negative book value of ₹-67.83 per share, reflecting a troubling financial position with shareholder equity at ₹-146.2...

Read full news article

Krebs Biochemicals & Industries Ltd Reports Flat Quarterly Performance Amid Prolonged Downtrend

2026-05-22 08:00:03

Krebs Biochemicals & Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a tentative stabilisation after a period of significant decline. Despite some improvement in quarterly profitability metrics, the company continues to grapple with steep revenue contraction and persistent losses over the nine-month period, reflecting ongoing challenges in its business operations and market positioning.

Read full news article

Krebs Biochemicals Q4 FY26: Mounting Losses Signal Deepening Crisis

2026-05-21 20:00:32

Krebs Biochemicals & Industries Ltd., a micro-cap pharmaceutical manufacturer specialising in Active Pharmaceutical Ingredients through fermentation, reported a net loss of ₹2.34 crores in Q4 FY26 (Mar'26), marking the seventh consecutive quarter of losses. With a market capitalisation of just ₹122.00 crores, the company's shares declined 2.15% to ₹53.81 following the results, extending a brutal 27.28% decline over the past year and trading 52.76% below its 52-week high of ₹113.90.

Read full news article